Patents by Inventor Elaine Harper

Elaine Harper has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RNA CONSTRUCT
    Publication number: 20240124530
    Abstract: The present invention relates to RNA constructs, and particularly, although not exclusively, to mRNA constructs and saRNA replicons and to nucleic acids and expression vectors encoding such RNA constructs. The invention extends to the use of such RNA constructs in therapy, for example in treating diseases and/or in vaccine delivery. The invention extends to pharmaceutical compositions comprising such RNA constructs, and methods and uses thereof.
    Type: Application
    Filed: December 17, 2021
    Publication date: April 18, 2024
    Applicants: Imperial College Innovations Limited, VaxEquity Ltd
    Inventors: Robin Shattock, Paul McKay, Michael Watson, Elaine Harper
  • RNA CONSTRUCT
    Publication number: 20230364226
    Abstract: The invention relates to RNA constructs, and particularly, although not exclusively, to mRNA constructs and saRNA replicons and to nucleic acids and expression vectors encoding such RNA constructs. The invention extends to the use of such RNA constructs in therapy, for example in treating diseases and/or in vaccine delivery. The invention extends to pharmaceutical compositions comprising such RNA constructs, and methods and uses thereof.
    Type: Application
    Filed: December 17, 2021
    Publication date: November 16, 2023
    Applicants: Imperial College Innovations Limited, VaxEquity Ltd
    Inventors: Robin Shattock, Paul McKay, Michael Watson, Elaine Harper
  • Therapeutic fusion proteins
    Patent number: 10704038
    Abstract: The present invention relates to the construction of a new class of Targeted Secretion Inhibitors (TSIs), which comprise a non-cytotoxic protease, translocation peptide and a targeting moiety peptide, wherein the targeting moiety peptide has a free N-terminal domain and a free C-terminal domain; to a single-chain fusion protein precursor thereof, and to a method of activating said single-chain fusion protein precursor.
    Type: Grant
    Filed: August 20, 2018
    Date of Patent: July 7, 2020
    Assignee: IPSEN BIOINNOVATION LIMTIED
    Inventors: John Chaddock, Elaine Harper
  • THERAPEUTIC FUSION PROTEINS
    Publication number: 20190062721
    Abstract: The present invention relates to the construction of a new class of Targeted Secretion Inhibitors (TSIs), which comprise a non-cytotoxic protease, translocation peptide and a targeting moiety peptide, wherein the targeting moiety peptide has a free N-terminal domain and a free C-terminal domain; to a single-chain fusion protein precursor thereof, and to a method of activating said single-chain fusion protein precursor.
    Type: Application
    Filed: August 20, 2018
    Publication date: February 28, 2019
    Applicant: Ipsen Bioinnovation Limited
    Inventors: John Chaddock, Elaine Harper
  • Therapeutic fusion proteins
    Patent number: 10081803
    Abstract: The present invention relates to the construction of a new class of Targeted Secretion Inhibitors (TSIs), which comprise a non-cytotoxic protease, translocation peptide and a targeting moiety peptide, wherein the targeting moiety peptide has a free N-terminal domain and a free C-terminal domain; to a single-chain fusion protein precursor thereof, and to a method of activating said single-chain fusion protein precursor.
    Type: Grant
    Filed: May 16, 2012
    Date of Patent: September 25, 2018
    Assignee: Ipsen Bioinnovation Limited
    Inventors: John Chaddock, Elaine Harper
  • Assay for assessment of endosomal transport
    Patent number: 9170252
    Abstract: The invention provides an assay and corresponding kit for assessing the delivery efficiency of a molecule into a eukaryotic cell (basic assay). The present invention also provides an assay and corresponding kit for assessing the inhibitory effect of a test molecule in relation to the before-mentioned basic assay.
    Type: Grant
    Filed: October 23, 2013
    Date of Patent: October 27, 2015
    Assignee: IPSEN BIOINNOVATION LIMITED
    Inventor: Elaine Harper
  • ASSAY FOR ASSESSMENT OF ENDOSOMAL TRANSPORT
    Publication number: 20150241408
    Abstract: The invention provides an assay and corresponding kit for assessing the delivery efficiency of a molecule into a eukaryotic cell (basic assay). The present invention also provides an assay and corresponding kit for assessing the inhibitory effect of a test molecule in relation to the before-mentioned basic assay.
    Type: Application
    Filed: October 23, 2013
    Publication date: August 27, 2015
    Inventor: Elaine Harper
  • THERAPEUTIC FUSION PROTEINS
    Publication number: 20140147429
    Abstract: The present invention relates to the construction of a new class of Targeted Secretion Inhibitors (TSIs), which comprise a non-cytotoxic protease, translocation peptide and a targeting moiety peptide, wherein the targeting moiety peptide has a free N-terminal domain and a free C-terminal domain; to a single-chain fusion protein precursor thereof, and to a method of activating said single-chain fusion protein precursor.
    Type: Application
    Filed: May 16, 2012
    Publication date: May 29, 2014
    Applicant: SYNTAXIN LIMITED
    Inventors: John Chaddock, Elaine Harper
  • Benzotriazepnes as gastrin and cholecystokinin receptor ligands
    Publication number: 20060003993
    Abstract: This invention relates to a compound of formula (I) wherein: W is N or N+—O?; and R1 to R5 are as defined in the description, for use for the treatment of gastrin related disorders.
    Type: Application
    Filed: November 12, 2002
    Publication date: January 5, 2006
    Applicant: James Black Foundation Limited
    Inventors: Iain McDonald, Ildiko Buck, Elaine Harper, Ian Linney, Michael Pether, Katherine Steel, Carol Austin, David Dunstone, Sarkis Kalindjian, Caroline Low, John Spencer, Paul Wright
  • Bicyclo 2,2,2!octane derivatives
    Patent number: 5514683
    Abstract: The compounds of the formula I ##STR1## and their pharmaceutical acceptable salts, which are defined herein, are ligands for cholecystokinin and/or gastrin receptors.
    Type: Grant
    Filed: August 9, 1994
    Date of Patent: May 7, 1996
    Assignee: James Black Foundation Limited
    Inventors: Sarkis B. Kalindjian, Caroline M. R. Low, Iain M. McDonald, Robert A. D. Hull, Nigel P. Shankley, Ildiko M. Buck, Katherine I. M. Steel, Jonathan M. R. Davies, David J. Dunstone, Elaine A. Harper, Michael J. Pether, Michael J. Bodkin, Matthew J. Tozer, Martin L. Hudson